VIRBAC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 349 EUR | +0.72% |
|
-7.18% | -2.92% |
| 04-17 | VIRBAC : A healthy start to 2024; outlook re-iterated |  |
| 04-17 | Virbac: sales up by almost 10% in Q1 | CF |
| Sales 2023 | 1.25B 1.33B 1.82B | Sales 2024 * | 1.38B 1.47B 2.01B | Capitalization | 2.92B 3.12B 4.27B |
|---|---|---|---|---|---|
| Net income 2023 | 121M 129M 177M | Net income 2024 * | 139M 149M 203M | EV / Sales 2023 | 2.39 x |
| Net cash position 2023 | 52.36M 55.99M 76.54M | Net Debt 2024 * | 73.54M 78.63M 107M | EV / Sales 2024 * | 2.17 x |
| P/E ratio 2023 |
25
x | P/E ratio 2024 * |
21.1
x | Employees | 5,459 |
| Yield 2023 |
0.37% | Yield 2024 * |
0.42% | Free-Float | 49.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on Virbac
More press releases
More news
| 1 day | +0.72% | ||
| 1 week | -7.18% | ||
| Current month | +0.87% | ||
| 1 month | +1.31% | ||
| 3 months | +3.25% | ||
| 6 months | +29.50% | ||
| Current year | -2.92% |
1 week
342.00
377.50
1 month
334.00377.50
Current year
316.50377.50
1 year
232.50377.50
3 years
215.00448.50
5 years
132.20448.50
10 years
102.10448.50
| Managers | Title | Age | Since |
|---|---|---|---|
Sébastien Huron
CEO | Chief Executive Officer | 54 | 05-12-31 |
Habib Ramdani
DFI | Director of Finance/CFO | 48 | 16-01-31 |
Sophie Favini
COO | Chief Operating Officer | - | 23-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 10-12-31 | |
Philippe Capron
BRD | Director/Board Member | 64 | 03-12-31 |
| Chairman | 59 | 97-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.25% | 1 M€ | -.--% | ||
| 0.02% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 349 | +0.72% | 7,198 |
| 24-04-25 | 346.5 | -3.75% | 5,641 |
| 24-04-24 | 360 | +0.28% | 1,844 |
| 24-04-23 | 359 | +0.56% | 6,389 |
| 24-04-22 | 357 | -5.05% | 5,462 |
Real-time Euronext Paris, April 26, 2024 at 11:35 am
More quotes
Virbac specializes in the research, production and marketing of veterinary medicines. The activity is organized around 2 product families:
- pet medications: pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips;
- livestock medications: pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc.
Net sales are distributed geographically as follows: France (15.8%), Europe (24.9%), Asia (17.5%), Latin America (16.2%), North America (13.3%), Pacific (9.7%), Africa and Middle East (2.6%).
Sector
Pharmaceuticals
Calendar
2024-06-20
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
349
EUR
Average target price
368
EUR
Spread / Average Target
+5.44%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.92% | 3.12B | |
| -19.73% | 72.39B | |
| -11.01% | 6.54B | |
| +15.88% | 3.43B | |
| -0.68% | 1.4B | |
| -17.27% | 1.34B | |
| -2.73% | 1.26B | |
| -14.67% | 1.12B | |
| -5.37% | 990M | |
| -24.06% | 805M |
- Stock Market
- Equities
- VIRP Stock
